Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 20
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publication Artículo científico (JournalArticle)

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  • Gutiérrez-Gutiérrez, Belén
  • Pérez-Galera, Salvador
  • Salamanca-Rivera, Elena
  • Cueto-López, Marina
  • Calbo, Esther
  • Almirante, Benito
  • Viale, Pier-Luigy
  • Oliver, Antonio
  • Pintado, Vicente
  • Gasch Blasi, Oriol
  • Martínez-Martínez, Luis
  • Pitout, Johann
  • Akova, Murat
  • Peña, Carmen
  • Molina Gil-Bermejo, José
  • Lorenzo-Hernández, Alicia
  • Venditti, Mario
  • Prim, Nuria
  • Origüen, Julia
  • Bou, Germán
  • Tacconelli, Evelina
  • Tumbarello, Mario
  • Hamprecht, Axel
  • Giamarellou, Helen
  • Almela, Manuel
  • Pérez, Federico J.
  • Schwaber, Mitchell J.
  • Bermejo, Joaquín
  • Lowman, Warren
  • Hsueh, Po-Ren
  • Mora-Rillo, Marta
  • Natera, Clara
  • Souli, Maria
  • Bonomo, Robert
  • Carmeli, Yehuda
  • Paterson, David L.
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Abstract] The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems., The work was funded by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofinanced by European Development Regional Fund titled A Way To Achieve Europe ERDF, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), and FIS (PI10/02021). Participants in the study received support for research from the Innovative Medicines Initiative Joint Undertaking under the Combatting Bacterial Resistance in Europe—Molecule against Gram Negative Infections (COMBACTE-MAGNET) agreement 115737 resources, which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in kind contributions (A. Pascua and J. Rodríguez-Baño), the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program, the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and NIAID, NIH, under award numbers R01AI072219 and R01AI063517 (R. A. Bonomo). The funding organizations had no role in the design or conduct of the study, collection, management analysis, or interpretation of the data, preparation, review or approval of the manuscript, or decision to submit the manuscript for publication.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

PRAISE: providing a roadmap for automated infection surveillance in Europe

  • van Mourik, Maaike S. M.
  • van Rooden, Stephanie M.
  • Abbas, Mohamed
  • Aspevall, Olov
  • Astagneau, Pascal
  • Bonten, Marc J.M.
  • Carrara, Elena
  • Gomila Grange, Aina
  • de Greeff, Sabine C.
  • Gubbels, Sophie
  • Harrison, Wendy
  • Humphreys, Hilary
  • Johansson, Anders
  • Koek, Mayke B.G.
  • Kristensen, Brian
  • Lepape, Alain
  • Lucet, Jean-Christophe
  • Mookerjee, Siddharth
  • Naucler, Pontus
  • Palacios Baena, Zaira R.
  • Presterl, Elisabeth
  • Pujol Rojo, Miquel
  • Reilly, Jacqui
  • Roberts, Christopher
  • Tacconelli, Evelina
  • Teixeira, Daniel
  • Tängdén, Thomas
  • Valik, John Karlsson
  • Behnke, Michael
  • Gastmeier, Petra
Introduction: Healthcare-associated infections (HAI) are among the most common adverse events of medical care. Surveillance of HAI is a key component of successful infection prevention programmes. Conventional surveillance - manual chart review - is resource intensive and limited by concerns regarding interrater reliability. This has led to the development and use of automated surveillance (AS). Many AS systems are the product of in-house development efforts and heterogeneous in their design and methods. With this roadmap, the PRAISE network aims to provide guidance on how to move AS from the research setting to large-scale implementation, and how to ensure the delivery of surveillance data that are uniform and useful for improvement of quality of care. Methods: The PRAISE network brings together 30 experts from ten European countries. This roadmap is based on the outcome of two workshops, teleconference meetings and review by an independent panel of international experts. Results: This roadmap focuses on the surveillance of HAI within networks of healthcare facilities for the purpose of comparison, prevention and quality improvement initiatives. The roadmap does the following: discusses the selection of surveillance targets, different organizational and methodologic approaches and their advantages, disadvantages and risks; defines key performance requirements of AS systems and suggestions for their design; provides guidance on successful implementation and maintenance; and discusses areas of future research and training requirements for the infection prevention and related disciplines. The roadmap is supported by accompanying documents regarding the governance and information technology aspects of implementing AS. Conclusions: Large-scale implementation of AS requires guidance and coordination within and across surveillance networks. Transitions to large-scale AS entail redevelopment of surveillance methods and their interpretation, intensive dialogue with stakeholders and the investment of considerable resources. This roadmap can be used to guide future steps towards implementation, including designing solutions for AS and practical guidance checklists.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study

  • Vallejo Torres, Laura
  • Pujol Rojo, Miquel
  • Shaw Perujo, Evelyn
  • Wiegand, Irith
  • Vigo, Joan Miquel
  • Stoddart, Margaret
  • Grier, Sally
  • Gibbs, Julie
  • Vank, Christiane
  • Cuperus, Nienke
  • van den Heuvel, Leonard
  • Eliakim-Raz, Noa
  • Carratalà, Jordi
  • Vuong, Cuong
  • MacGowan, Alasdair
  • Babich, Tanya
  • Leibovici, Leonard
  • Addy, Ibironke
  • Morris, S. (Stephen), 1971-
  • RESCUING Study Group and Study Sites
Objective: Complicated urinary tract infections (cUTIs) impose a high burden on healthcare systems and are a frequent cause of hospitalisation. The aims of this paper are to estimate the cost per episode of patients hospitalised due to cUTI and to explore the factors associated with cUTI-related healthcare costs in eight countries with high prevalence of multidrug resistance (MDR). Design: This is a multinational observational, retrospective study. The mean cost per episode was computed by multiplying the volume of healthcare use for each patient by the unit cost of each item of care and summing across all components. Costs were measured from the hospital perspective. Patient-level regression analyses were used to identify the factors explaining variation in cUTI-related costs. Setting: The study was conducted in 20 hospitals in eight countries with high prevalence of multidrug resistant Gram-negative bacteria (Bulgaria, Greece, Hungary, Israel, Italy, Romania, Spain and Turkey). Participants: Data were obtained from 644 episodes of patients hospitalised due to cUTI. Results: The mean cost per case was 5700, with considerable variation between countries (largest value 7740 in Turkey; lowest value 4028 in Israel), mainly due to differences in length of hospital stay. Factors associated with higher costs per patient were: type of admission, infection source, infection severity, the Charlson comorbidity index and presence of MDR. Conclusions: The mean cost per hospitalised case of cUTI was substantial and varied significantly between countries. A better knowledge of the reasons for variations in length of stays could facilitate a better standardised quality of care for patients with cUTI and allow a more efficient allocation of healthcare resources. Urgent admissions, infections due to an indwelling urinary catheterisation, resulting in septic shock or severe sepsis, in patients with comorbidities and presenting MDR were related to a higher cost.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING)

  • Shaw Perujo, Evelyn
  • Addy, Ibironke
  • Stoddart, Margaret
  • Vank, Christiane
  • Grier, Sally
  • Wiegand, Irith
  • Leibovici, Leonard
  • Eliakim-Raz, Noa
  • Vallejo Torres, Laura
  • Morris, S. (Stephen), 1971-
  • MacGowan, Alasdair
  • Carratalà, Jordi
  • Pujol Rojo, Miquel
Introduction: the emergence of multidrug resistant (MDR) Gram-negative bacteria (GNB), including carbapenemase-producing strains, has become a major therapeutic challenge. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. The study has been designed to gain insight into the epidemiology, clinical management, outcome and healthcare cost of patients with cUTI, especially in countries with high prevalence of MDR GNB. Methods and analysis: this multinational and multicentre observational, retrospective study will identify cases from 1 January 2013 to 31 December 2014 in order to collect data on patients with cUTI as a cause of hospital admission, and patients who develop cUTI during their hospital stay. The primary end point will be treatment failure defined as the presence of any of the following criteria: (1) signs or symptoms of cUTI present at diagnosis that have not improved by days 5-7 with appropriate antibiotic therapy, (2) new cUTI-related symptoms that have developed within 30 days of diagnosis, (3) urine culture taken within 30 days of diagnosis, either during or after completion of therapy, that grows ≥10(4) colony-forming unit/mL of the original pathogen and (4) death irrespective of cause within 30 days of the cUTI diagnosis. Sample size: 1000 patients afford a power of 0.83 (α=0.05) to detect an absolute difference of 10% in the treatment failure rate between MDR bacteria and other pathogens. This should allow for the introduction of about 20 independent risk factors (or their interaction) in a logistic regression model looking at risk factors for failure. Ethics and dissemination: approval will be sought from all relevant Research Ethics Committees. Publication of this study will be considered as a joint publication by the participating investigator leads, and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Surveillance Systems from Public Health Institutions and Scientific Societies for Antimicrobial Resistance and Healthcare-Associated Infections in Europe (SUSPIRE): protocol for a systematic review

  • Núñez Núñez, María
  • Navarro-Amuedo, María Dolores
  • Gkolia, Panagiota
  • Nithya, Babu Rajendran
  • Toro Crespo, M. de
  • Voss, Andreas
  • Sharland, Mike
  • Sifakis, Frangiscos
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
EPI-NET group., [Introduction] The worldwide spread of antimicrobial resistance is now recognised as a global public health threat. Owing to the geographical heterogeneity, complexity and continuously evolving dynamics of resistant organisms and genes, surveillance is a key tool for understanding, measuring and informing actions in the fight against this problem. To date there is no harmonisation of key indicators or of methodologies used to obtain them., [Methods and analysis] The main objective of this project is to systematically review and analyse the current publicly available surveillance activities on antimicrobial resistance and healthcare-associated infections in Europe. Eligible activities are those endorsed by regional, national or transnational health organisations and scientific societies providing data on a periodic basis. Grey and peer-reviewed literature will be searched with no language restrictions. Three independent reviewers will perform a two-step selection process using a previously piloted, tailored electronic data extraction form. Descriptive summaries and tables of all relevant findings will be performed and reported according to PRISMA guidelines., [Ethics and dissemination] We did not seek ethical approval for this study because the data to be collected are not linked to individuals. Data will be presented at international conferences and published in peer-reviewed journals., [Trial registration number] CRD42016033867., This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007/2013) and EFPIA companies in kind contribution. JRB also received funding for research from Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—cofinanced by European Development Regional Fund ‘A way to achieve Europe’ ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A Multinational, Preregistered Cohort Study of β-Lactam/β-Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  • Gutiérrez-Gutiérrez, Belén
  • Pérez-Galera, Salvador
  • Salamanca, Elena
  • Cueto, Marina de
  • Calbo, Esther
  • Almirante, Benito
  • Viale, Pierluigi
  • Oliver, Antonio
  • Pintado, Vicente
  • Gasch, Oriol
  • Martínez-Martínez, Luis
  • Pitout, Johann
  • Akova, Murat
  • Peña, Carmen
  • Molina Gil-Bermejo, José
  • Hernández, Alicia
  • Venditti, Mario
  • Prim, Nuria
  • Origüen, Julia
  • Bou, Germán
  • Tacconelli, Evelina
  • Tumbarello, Mario
  • Hamprecht, Axel
  • Giamarellou, Helen
  • Almela, Manel
  • Pérez, Federico
  • Schwaber, Mitchell J.
  • Bermejo, Joaquín
  • Lowman, Warren
  • Hsueh, Po-Ren
  • Mora-Rillo, Marta
  • Natera Kindelán, Clara
  • Souli, María
  • Bonomo, Robert A.
  • Carmeli, Yehuda
  • Paterson, David L.
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
The spread of extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) is leading to increased carbapenem consumption. Alternatives to carbapenems need to be investigated. We investigated whether β-lactam/β-lactamase inhibitor (BLBLI) combinations are as effective as carbapenems in the treatment of bloodstream infections (BSI) due to ESBL-E. A multinational, retrospective cohort study was performed. Patients with monomicrobial BSI due to ESBL-E were studied; specific criteria were applied for inclusion of patients in the empirical-therapy (ET) cohort (ETC; 365 patients), targeted-therapy (TT) cohort (TTC; 601 patients), and global cohort (GC; 627 patients). The main outcome variables were cure/improvement rate at day 14 and all-cause 30-day mortality. Multivariate analysis, propensity scores (PS), and sensitivity analyses were used to control for confounding. The cure/improvement rates with BLBLIs and carbapenems were 80.0% and 78.9% in the ETC and 90.2% and 85.5% in the TTC, respectively. The 30-day mortality rates were 17.6% and 20% in the ETC and 9.8% and 13.9% in the TTC, respectively. The adjusted odds ratio (OR) (95% confidence interval [CI]) values for cure/improvement rate with ET with BLBLIs were 1.37 (0.69 to 2.76); for TT, they were 1.61 (0.58 to 4.86). Regarding 30-day mortality, the adjusted OR (95% CI) values were 0.55 (0.25 to 1.18) for ET and 0.59 (0.19 to 1.71) for TT. The results were consistent in all subgroups studied, in a stratified analysis according to quartiles of PS, in PS-matched cases, and in the GC. BLBLIs, if active in vitro, appear to be as effective as carbapenems for ET and TT of BSI due to ESLB-E regardless of the source and specific species. These data may help to avoid the overuse of carbapenems. (This study has been registered at ClinicalTrials.gov under registration no. NCT01764490.), The work was funded by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofinanced by European Development Regional Fund titled A Way To Achieve Europe ERDF, the Spanish Network for Research in Infectious Diseases (REIPI RD12/0015), and FIS (PI10/02021). Participants in the study received support for research from the Innovative Medicines Initiative Joint Undertaking under the Combatting Bacterial Resistance in Europe—Molecule against Gram Negative Infections (COMBACTE-MAGNET) agreement 115737 resources, which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/2007-2013) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) companies' in kind contributions (A. Pascua and J. Rodríguez-Baño), the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program, the Geriatric Research Education and Clinical Center VISN 10 (VISN 10 GRECC), and NIAID, NIH, under award numbers R01AI072219 and R01AI063517 (R. A. Bonomo)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The Methodology of Surveillance for Antimicrobial Resistance and Healthcare-Associated Infections in Europe (SUSPIRE): A Systematic Review of Publicly Available Information

  • Núñez Núñez, María
  • Navarro-Amuedo, María Dolores
  • Palomo, Virginia
  • Rajendran, N. B.
  • Toro, María Dolores del
  • Voss, Andreas
  • Sharland, Mike
  • Sifakis, Frangiscos
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
EPI-Net, Combacte-Magnet and EUCIC Group for SUSPIRE: F. Burkert, E. Carrara, M. von Cube, L. Drgona, K. Gilchrist, H. Goossens, S. Harbarth, D. Hequet, H. Jafri, G. Kahlmeter, S. Kuster, C. Luxemburger, M. McCarthy, M. Niks, A. Oualim, M. Poljak, O. Sandulescu, A. Schweiger, C. Vuong, I. Wiegand, A. Widmer, A. T. Witschi, G. Zanetti, W. Zingg., [Objectives] Surveillance is a key component of any control strategy for healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), and public availability of methodologic aspects is crucial for the interpretation of the data. We sought to systematically review publicly available information for HAIs and/or AMR surveillance systems organized by public institutions or scientific societies in European countries., [Methods] A systematic review of scientific and grey literature following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed. Information on HAIs and/or AMR surveillance systems published until 31 October 2016 were included., [Results] A total of 112 surveillance systems were detected; 56 from 20 countries were finally included. Most exclusions were due to lack of publicly available information. Regarding AMR, the most frequent indicator was the proportion of resistant isolates (27 of 34 providing information, 79.42%); only 18 (52.9%) included incidence rates; the data were only laboratory based in 33 (78.5%) of the 42 providing this information. Regarding HAIs in intensive care units, all 22 of the systems providing data included central line–associated bloodstream infections, and 19 (86.3%) included ventilator-associated pneumonia and catheter-associated urinary tract infections; incidence density was the most frequent indicator. Regarding surgical site infections, the most frequent procedures included were hip prosthesis, colon surgery and caesarean section (21/22, 95.5%)., [Conclusions] Publicly available information about the methods and indicators of the surveillance system is frequently lacking. Despite the efforts of European Centre for Disease Control and Prevention (ECDC) and other organizations, wide heterogeneity in procedures and indicators still exists., Funded by the Innovative Medicines Initiative (IMI), New Drugs for Bad Bugs (ND4BB) programme, European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA (European Federation of Pharmaceutical Industries and Association) companies' in-kind contribution (IMI 11th) under grant 115737, COMBACTE-MAGNET (Combatting bacterial resistance in Europe—Molecule against Gram negative infections). JRB and MDT receive funding for research from Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, cofinanced by European Regional Development Fund (ERDF) ‘A way to achieve Europe,’ Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015 and REIPI RD16/0016).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature

  • Grabein, B.
  • Graninger, W.
  • Rodríguez-Baño, Jesús
  • Dinh, A.
  • Liesenfeld, D. B.
[Objectives] We conducted a systematic review and meta-analysis to summarize the clinical evidence and usage patterns of intravenous fosfomycin from its development to the present time., [Methods] PubMed, the Cochrane Library and local journals were searched for relevant studies reporting aggregated data of intravenous fosfomycin use in adults and children, with no restrictions regarding study design. Single case reports were excluded. Data were systematically abstracted for all included studies. Clinical and microbiological efficacy from randomized controlled and comparative observational studies were synthesized using meta-analysis to calculate pooled effect sizes., [Results] In all, 128 studies on intravenous fosfomycin in 5527 patients were evaluated. Fosfomycin was predominantly used for sepsis/bacteraemia, urinary tract, respiratory tract, bone and joint, and central nervous system infections. No difference in clinical (OR 1.44, 95% CI 0.96–2.15) or microbiological (OR 1.28, 95% CI 0.82–2.01) efficacy between fosfomycin and other antibiotics was observed in comparative trials. The pooled estimate for resistance development during fosfomycin monotherapy was 3.4% (95% CI 1.8%–5.1%). Fosfomycin showed a favourable safety profile, with generally mild adverse events not requiring discontinuation of treatment. Included studies explored intravenous fosfomycin as an anti-staphylococcal agent in monotherapy and combination therapy, whereas studies from 1990 focused on combination therapy (fosfoymcin + β-lactams or aminoglycosides) for challenging infections frequently caused by multidrug-resistant organisms., [Conclusion] Intravenous fosfomycin can play a vital role in the antibiotic armamentarium, given its long history of effective and safe use. However, well-designed randomized controlled trials are still desired., All authors approved the final version of the manuscript. JRB receives funding for research from the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund “A way to achieve Europe” ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015), FIS (PI 13/01282), and the Innovative Medicines Initiative (European Union and EFPIA partners in kind; agreements 115523 COMBACTE-NET, 115620 COMBACTE-CARE and 115737 COMBACTE-MAGNET projects).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition

  • Harris, Patrick N.A.
  • McNamara, J. F.
  • Lye, D. C.
  • Davis, J. S.
  • Bernard, Louis
  • Cheng, A. C.
  • Doi, Y.
  • Fowler, Vance G.
  • Kaye, K. S.
  • Leibovici, Leonard
  • Lipman, Jeffrey
  • Llewelyn, Martin J.
  • Muñoz-Price, S.
  • Paul, Mical
  • Peleg, A. Y.
  • Rodríguez-Baño, Jesús
  • Rogers, B. A.
  • Seifert, Harald
  • Thamlikitkul, V.
  • Thwaites, Guy
  • Tong, S. Y. C.
  • Turnidge, J.
  • Utili, R.
  • Webb, S. A. R.
  • Paterson, David L.
[Objectives] To define standardized endpoints to aid the design of trials that compare antibiotic therapies for bloodstream infections (BSI)., [Methods] Prospective studies, randomized trials or registered protocols comparing antibiotic therapies for BSI, published from 2005 to 2016, were reviewed. Consensus endpoints for BSI studies were defined using a modified Delphi process., [Results] Different primary and secondary endpoints were defined for pilot (small-scale studies designed to evaluate protocol design, feasibility and implementation) and definitive trials (larger-scale studies designed to test hypotheses and influence clinical practice), as well as for Staphylococcus aureus and Gram-negative BSI. For pilot studies of S. aureus BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever, stable/improved Sequential Organ Failure Assessment (SOFA) score and clearance of blood cultures, with no microbiologically confirmed failure up to 90 days. For definitive S. aureus BSI studies, a primary outcome of success at 90 days was defined by survival and no microbiologically confirmed failure. For pilot studies of Gram-negative BSI, a primary outcome of success at day 7 was defined by: survival, resolution of fever and symptoms related to BSI source, stable or improved SOFA score and negative blood cultures. For definitive Gram-negative BSI studies, a primary outcome of survival at 90 days supported by a secondary outcome of success at day 7 (as previously defined) was agreed., [Conclusions] These endpoints provide a framework to aid future trial design. Further work will be required to validate these endpoints with respect to patient-centred clinical outcomes., PH is supported by an Australian Postgraduate Award from the University of Queensland. VGF was supported by R01AI068804 from National Institutes of Health. KSK is supported by the National Institute of Allergy and Infectious Diseases (NIAID), DMID Protocol no. 10-0065 and R01AI119446. ACC and AYP were supported by an Australian National Health and Medical Research Council Career Development Fellowship. HS receives funding from the German Centre for Infection Research (DZIF), Germany. JRB receives funding for research from Ministerio de Economía y Competitividad, Instituto de Salud Carlos III—co-financed by European Development Regional Fund ‘A way to achieve Europe' ERDF, Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015). JRB and MP receive funding from Innovatives Medicine Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies (COMBACTE, COMBACTE-CARE and COMBACTE-MAGNET projects, grant agreements 1155223, 115620 and 115737). RU and MP are supported by the European Union 7th Framework Programme (Project ‘AIDA’). SYCT is supported by an NHMRC Career Development Fellowship 1065736. JT received funding from NHMRC (Project Grant ID 1044941).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Role of inoculum and mutant frequency on fosfomycin MIC discrepancies by agar dilution and broth microdilution methods in Enterobacteriaceae

  • Ballestero-Téllez, Mónica
  • Docobo-Pérez, Fernando
  • Rodríguez-Martínez, José-Manuel
  • Conejo, M. Carmen
  • Ramos-Guelfo, M. S.
  • Blázquez Gómez, Jesús
  • Rodríguez-Baño, Jesús
  • Pascual Bravo, Alberto
[Objectives] Fosfomycin is re-evaluated as a treatment of multidrug-resistant Enterobacteriaceae infections. However, MIC differences have been described among the different susceptibility testing. The aim was to study the role of the different inoculum size used in agar dilution with respect to broth microdilution, according to CLSI, in the fosfomycin MIC discrepancies., [Methods] Fosfomycin MICs were determined using agar dilution (reference) and broth microdilution in 220 Escherichia coli (n = 81) and Klebsiella pneumoniae (n = 139) clinical isolates. Fosfomycin mutant frequencies were determined in 21 E. coli (MIC = 1 mg/L) and 21 K. pneumoniae (MIC = 16 mg/L). The emergence of resistant subpopulations of five E. coli strains (MIC = 1 mg/L) was monitored over the time by microdilution assay using 0, 4 and 8 mg/L of fosfomycin, and eight different inocula (5 × 105−3.91 × 103 CFU/well, 1 : 2 dilutions)., [Results] For E. coli, 86.4% of categorical agreement (CA), 9.1% very major errors (VME), 3.3% major errors (ME) and 9.9% minor errors (mE) were found. For K. pneumoniae, CA was 51.1%, VME 15.7%, ME 28.4% and mE 25.2%. Essential agreement (±1–log2) was observed in 55.45%. By microdilution, 35.9% of the MICs showed discrepancies of ≥2 dilutions. Initial inoculum used was 5.63 times higher in the microdilution method, in range with CLSI methodology for both techniques. Fosfomycin mutant frequencies were 6.05 × 10–5 (4 × MIC) to 5.59 × 10–7 (256 × MIC) for E. coli, and 1.49 × 10–4 (4 × MIC) to 1.58 × 10–5 (16 × MIC) for K. pneumoniae. Resistant subpopulations arose mainly after 8 h of incubation with inocula >3.13 × 104 CFU/well., [Conclusions] The higher inoculum used in the microdilution method enriched the initial inoculum with resistant subpopulations and could partially explain the fosfomycin MIC discrepancies with respect to the agar dilution method., This work was supported by the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III (PI13/01885 and PI13/01282) and the Consejería de Salud, Junta de Andalucía (PI-0044-2013), Spain. It was partially supported by Plan Nacional de I+D+i and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD12/0015)—co-financed by European Development Regional Fund ‘A way to achieve Europe’ ERDF. Fernando Docobo-Pérez is supported by a VPPI-US fellowship from the University of Sevilla. JRB acts as scientific advisor for AstraZeneca, Merck and Achaogen, and was speaker for AstraZeneca, Merck, Pfizer and Astellas. He received funding for research from 115523 COMBACTE-NET, 115620 COMBACTE-CARE, and 115737 COMBACTE-MAGNET projects, Innovative Medicines Initiative (IMI), funded by the European Union and EFPIA companies.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mandatory surveillance and outbreaks reporting of the WHO priority pathogens for research & discovery of new antibiotics in European countries

  • Rajendran, N. B.
  • Mutters, Nico T.
  • Marasca, G.
  • Conti, Marta
  • Sifakis, Frangiscos
  • Vuong, C.
  • Voss, Andreas
  • Rodríguez-Baño, Jesús
  • Tacconelli, Evelina
For the COMBACTE-MAGNET-EPI-Net Consortium. In Press., [Objectives] In 2017 the WHO published a global priority list of 12 antibiotic-resistant bacteria (ARB) in urgent need of new antibiotics. We aimed to identify and assess publicly accessible mandatory surveillance systems and outbreaks reporting for these pathogens in the 28 European Union and four European Free Trade Association member states. [Methods] Compulsory reporting was mapped by reviewing national documents without applying language restrictions and through expert consultation. Information on surveillance targets, indicators, metrics and dissemination modalities was extracted and a qualitative assessment was performed for open access systems only. [Results] Twenty-one countries (66%) had a mandate to survey at least one among the 12 WHO priority pathogens; 15 provided access to surveillance frameworks. These systems covered most frequently carbapenem-resistant Enterobacteriales (12; 38%), methicillin-resistant Staphylococcus aureus (12; 38%), and vancomycin-resistant enterococci (8; 25%). None of the European countries required reporting of resistance in Salmonella, Campylobacter, Helicobacter pylori and Neisseria gonorrhoeae. High heterogeneity was observed in data collection, reporting and dissemination among countries with clinical outcomes and risk factors being reported in less than half (22% and 25%). Only six countries (19%) implemented mandatory surveillance of outbreaks due to at least one WHO priority pathogen. [Conclusions] Our review shows that despite the increasing burden of ARB on the European population, very few countries implemented mandatory surveillance and outbreak reporting of the WHO priority pathogens. International efforts are needed to define the effectiveness of implementing mandatory reporting of these pathogens and to assess their role in reducing the spread of ARB in health-care and community settings., This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement numbers 115737 (COMBACTE-MAGNET), resources of which are composed of financial contributions from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Systematic literature review of the burden and outcomes of infections due to multidrug-resistant organisms in Europe: the ABOUT-MDRO project protocol

  • Anaya-Baz, Blanca
  • Maldonado, Natalia
  • Palacios-Baena, Zaira Raquel
  • Palomo, Virginia
  • Pezzani, Maria Diletta
  • Chiesi, Sheila
  • Razzaboni, Elisa
  • Compri, Monica
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
[Introduction] Despite the increasing importance of infections due to multidrug-resistant organisms (MDROs), there is a lack of comprehensive information about the burden of disease and outcomes of key infections caused by these pathogens. The aim of the ABOUT-MDRO (A systematic review on the burden and outcomes of infections due to multidrug resitant organisms) project is to provide estimations of the burden of some key infections and their outcomes caused by the target MDROs., [Methods and analysis] A systematic literature search will be performed using MEDLINE/PubMed, Elsevier’s SCOPUS, Cochrane library, Clinical trials and Web of Science, as well as the Surveillance Systems from Public Health Institutions and Scientific Societies for Antimicrobial Resistance and Healthcare-Associated Infections in Europe database of European surveillance systems, for data on prevalence/incidence, mortality and length of stay of target infections in hospitalised patients (including ventilator-associated pneumonia, hospital-acquired pneumonia, complicated intra-abdominal infections, complicated urinary tract infections, skin and soft tissue infections and bloodstream infections) and in specific populations (children, hospital wards, neutropenic patients) caused by cephalosporin-resistant or carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp., methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus spp. The information retrieved will be tabulated and pooled estimates and 95% CIs calculated of rates and outcomes, using random effects models. Relationships between rates and outcomes in randomised control trials and epidemiological studies, and data of proportions and incidence/prevalence rates will also be analysed. The information collected in this study will be useful for identifying gaps in our knowledge in terms of incidence/prevalence and clinical outcomes of infections caused by MDROs, and for informing priorities in infection control and the research and design of appropriate studies., [Ethics and dissemination] This study will be based on published data so we did not require ethical approval. Formal consent is not required. The results of this review will be reported according to the Preferred Reporting Items for Systematic Review and Meta-Analyses statement. Data will be presented at international conferences and published in peer-reviewed journals., [Registration details] PROSPERO (https://www.crd.york.ac.uk/prospero/) (CRD42019124185)., The ABOUT-MDRO Study is part of the COMBACTE-MAGNET project (Combatting Bacterial Resistance in Europe - Molecules against Gram-negative Infections), Innovative Medicines Initiative (IMI), European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in-kind contribution, Grant agreement 115737. ZRP-B and JR-B received funding for research from Plan Nacional de I+D+i 2013‐2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), co-financed by the European Development Regional Fund 'A way to achieve Europe', Operative Programme Intelligent Growth 2014‐2020.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Household acquisition and transmission of extended-spectrum β-lactamase (ESBL) -producing Enterobacteriaceae after hospital discharge of ESBL-positive index patients

  • Riccio, María E.
  • Verschuuren, Tess
  • Conzelmann, Nadine
  • Martak, Daniel
  • Meunier, Alexandre
  • Salamanca, Elena
  • Delgado-Valverde, Mercedes
  • Guther, Julia
  • Peter, Silke
  • Paganini, Julian
  • Martischang, Romain
  • Sauser, Julien
  • Kraker, Marlieke de
  • Cherkaoui, Abdessalam
  • Fluit, Ad C.
  • Cooper, Ben S.
  • Hocquet, Didier
  • Kluytmans, Jan
  • Tacconelli, Evelina
  • Rodríguez-Baño, Jesús
  • Harbarth, Stephan
MODERN WP2 study group: Caroline Brossier, Elodie von Dach, Gesuele Renzi, Jacques Schrenzel, Stefanie Bunk, Siri Goepel, Florian Hölzl, Michael Eib, Ingo B.Autenrieth, Álvaro Pascual, Xavier Bertrand, Jelle Scharringa, Patrick Musicha., [Objectives] This study aimed to determine rates and risk factors of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) acquisition and transmission within households after hospital discharge of an ESBL-PE-positive index patient., [Methods] Two-year prospective cohort study in five European cities. Patients colonized with ESBL-producing Escherichia coli (ESBL-Ec) or Klebsiella pneumoniae (ESBL-Kp), and their household contacts were followed up for 4 months after hospital discharge of the index case. At each follow up, participants provided a faecal sample and personal information. ESBL-PE whole-genome sequences were compared using pairwise single nucleotide polymorphism-based analysis., [Results] We enrolled 71 index patients carrying ESBL-Ec (n = 45), ESBL-Kp (n = 20) or both (n = 6), and 102 household contacts. The incidence of any ESBL-PE acquisition among household members initially free of ESBL-PE was 1.9/100 participant-weeks at risk. Nineteen clonally related household transmissions occurred (case to contact: 13; contact to case: 6), with an overall rate of 1.18 transmissions/100 participant-weeks at risk. Most of the acquisition and transmission events occurred within the first 2 months after discharge. The rate of ESBL-Kp household transmission (1.16/100 participant-weeks) was higher than of ESBL-Ec (0.93/100 participant-weeks), whereas more acquisitions were noted for ESBL-Ec (1.06/100 participant-weeks) compared with ESBL-Kp (0.65/100 participant-weeks). Providing assistance for urinary and faecal excretion to the index case by household members increased the risk of ESBL-PE transmission (adjusted prevalence ratio 4.3; 95% CI 1.3–14.1)., [Conclusions] ESBL-PE cases discharged from the hospital are an important source of ESBL-PE transmission within households. Most acquisition and transmission events occurred during the first 2 months after hospital discharge and were causally related to care activities at home, highlighting the importance of hygiene measures in community settings., [Clinical study registration] German Clinical Trials Register, DRKS-ID: DRKS00013250., This study was part of a Joint Programming Initiative on Antimicrobial Resistance collaborative research project, under the 2016 Joint Call framework (Transnational Research Projects on the Transmission Dynamics of Antibacterial Resistance). It received funding from the following national research agencies: Instituto de Salud Carlos III (grant no. AC16/00076), Netherlands Organization for Health Research and Development (grant no. AC681055), Swiss National Science Foundation (grant no. 40AR40-173608), German Federal Ministry of Education and Research (grant no. 01KI1830) and Agence Nationale de la Recherche (grant no. ANR-16-JPEC-0007-03). As part of a separate research project, Marlieke de Kraker has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement nos 115523, 115620 and 115737 (Combatting Bacterial Resistance in Europe projects (COMBACTE)), resources of which are composed of financial contribution from the European Union's 7th Framework Programme (FP7/2007±2013) and the European Federation of Pharmaceutical Industries and associations companies' in-kind contribution. Also, Elena Salamanca, Mercedes Delgado and Jesús Rodríguez-Baño received support for research from by the Plan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001), co-financed by the European Development Regional Fund ‘A way to achieve Europe’, Operative Programme Intelligence Growth 2014-2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

PRAISE: providing a roadmap for automated infection surveillance in Europe

  • van Mourik, Maaike S.M.
  • van Rooden, Stephanie M.
  • Abbas, Mohamed
  • Aspevall, Olov
  • Astagneau, Pascal
  • Bonten, Marc J. M.
  • Carrara, Elena
  • Gomila-Grange, Aina
  • de Greeff, Sabine C.
  • Gubbels, Sophie
  • Harrison, Wendy
  • Humphreys, Hilary
  • Johansson, Andres
  • Koek, Mayke B.G.
  • Kristensen, Brian
  • Lepape, Alain
  • Lucet, Jean-Christophe
  • Mookerjee, Siddharth
  • Naucler, Pontus
  • Palacios-Baena, Zaira Raquel
  • Presterl, Elisabeth
  • Pujol, Miquel
  • Reilly, Jacqui
  • Roberts, Christopher
  • Tacconelli, Evelina
  • Teixeira, Daniel
  • Tängdén, Thomas
  • Karlsson Valik, John
  • Behnke, Michael
  • Gastmeier, Petra
[Introduction] Healthcare-associated infections (HAI) are among the most common adverse events of medical care. Surveillance of HAI is a key component of successful infection prevention programmes. Conventional surveillance – manual chart review – is resource intensive and limited by concerns regarding interrater reliability. This has led to the development and use of automated surveillance (AS). Many AS systems are the product of in-house development efforts and heterogeneous in their design and methods. With this roadmap, the PRAISE network aims to provide guidance on how to move AS from the research setting to large-scale implementation, and how to ensure the delivery of surveillance data that are uniform and useful for improvement of quality of care., [Methods] The PRAISE network brings together 30 experts from ten European countries. This roadmap is based on the outcome of two workshops, teleconference meetings and review by an independent panel of international experts., [Results] This roadmap focuses on the surveillance of HAI within networks of healthcare facilities for the purpose of comparison, prevention and quality improvement initiatives. The roadmap does the following: discusses the selection of surveillance targets, different organizational and methodologic approaches and their advantages, disadvantages and risks; defines key performance requirements of AS systems and suggestions for their design; provides guidance on successful implementation and maintenance; and discusses areas of future research and training requirements for the infection prevention and related disciplines. The roadmap is supported by accompanying documents regarding the governance and information technology aspects of implementing AS., [Conclusions] Large-scale implementation of AS requires guidance and coordination within and across surveillance networks. Transitions to large-scale AS entail redevelopment of surveillance methods and their interpretation, intensive dialogue with stakeholders and the investment of considerable resources. This roadmap can be used to guide future steps towards implementation, including designing solutions for AS and practical guidance checklists., This network has been supported under the 7th transnational call within the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), Network Call on Surveillance (2018) and was thereby funded by ZonMw (grant 549007001). This project also received support from the COMBACTE MAGNET EPI-Net project funded by the Innovative Medicines Initiative Joint Undertaking under grant agreement 115523 | 115620 | 115737 | 777362, resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution. J.K.V. was supported by grants from Region Stockholm and Vinnova. H.H. reports grants from Pfizer and Astellas as well as personal fees from Pfizer outside the submitted work., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

What is the evidence base of used aggregated antibiotic resistance percentages to change empirical antibiotic treatment? A scoping review

  • Auzin, Ali
  • Spits, Menoeska
  • Tacconelli, Evelina
  • Rodríguez-Baño, José
  • Hulscher, Marlies
  • Adang, Eddy
  • Voss, Andreas
  • Wertheim, Heiman
[Objectives] Antibiotic resistance requires continuous monitoring by experts to decide whether empirical antibiotic therapies (EATs) should be replaced by alternative antibiotics. The exact moment and criteria for this change are unclear and generally based on consensus between experts. This scoping review aims to identify from the literature the resistance thresholds used for a change in EAT and the criteria on which they are based., [Methods] Scoping review for which a comprehensive structured literature search was conducted. Rayyan, software for systematic reviews, was used for the screening of abstracts and titles. Data sources were Pubmed and a hand-search of reference lists and grey literature. Papers were eligible if they concerned any type of bacterial infectious disease and mentioned or defined antibiotic resistance thresholds for decision-making purposes for EAT. The inclusion and analysis of articles was done by two researchers; any conflicts were resolved through discussion or by consulting a third reviewer., [Results] We identified 3146 unique papers. Following title/abstract screening, 125 papers were comprehensively read, and 16 papers were included. The included papers gave thresholds for urinary tract infections, respiratory tract infections, meningitis, skin and soft tissue infections, gonorrhoea, and bone and joint infections. Six criteria were found that were commonly used to base the thresholds on. These were: disease severity, efficacy of treatment, adverse drug events, risk of Clostridioides difficile infection, costs, and increased resistance. The number of criteria used to define each threshold varied from one to six between papers., [Conclusions] The thresholds used for EATs are few, commonly based on expert opinion estimates, and can therefore have broad ranges. Used criteria underlying reported thresholds are heterogenous and require standardization. Considering the rising trend in resistance, there is a clear need for rigid tools to determine thresholds in order to support guideline development with the best and timely evidence., This research was funded by the EPI-Net COMBACTE-MAGNET project. We thank the Innovative Medicines Initiative Joint Undertaking for supporting the EPI-Net COMBACTE-MAGNET project (grant agreement number 115737), resources of which include a financial contribution from the European Union Seventh Framework Program (FP7/2007–2013) and European Federation of Pharmaceutical Industries and Associations in-kind contribution., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PRAISE: providing a roadmap for automated infection surveillance in Europe

  • van Mourik, Maaike S. M.
  • van Rooden, Stephanie M.
  • Abbas, Mohamed
  • Aspevall, Olov
  • Astagneau, Pascal
  • Bonten, Marc J.M.
  • Carrara, Elena
  • Gomila Grange, Aina
  • de Greeff, Sabine C.
  • Gubbels, Sophie
  • Harrison, Wendy
  • Humphreys, Hilary
  • Johansson, Anders
  • Koek, Mayke B.G.
  • Kristensen, Brian
  • Lepape, Alain
  • Lucet, Jean-Christophe
  • Mookerjee, Siddharth
  • Naucler, Pontus
  • Palacios Baena, Zaira R.
  • Presterl, Elisabeth
  • Pujol Rojo, Miquel
  • Reilly, Jacqui
  • Roberts, Christopher
  • Tacconelli, Evelina
  • Teixeira, Daniel
  • Tängdén, Thomas
  • Valik, John Karlsson
  • Behnke, Michael
  • Gastmeier, Petra
Introduction: Healthcare-associated infections (HAI) are among the most common adverse events of medical care. Surveillance of HAI is a key component of successful infection prevention programmes. Conventional surveillance - manual chart review - is resource intensive and limited by concerns regarding interrater reliability. This has led to the development and use of automated surveillance (AS). Many AS systems are the product of in-house development efforts and heterogeneous in their design and methods. With this roadmap, the PRAISE network aims to provide guidance on how to move AS from the research setting to large-scale implementation, and how to ensure the delivery of surveillance data that are uniform and useful for improvement of quality of care. Methods: The PRAISE network brings together 30 experts from ten European countries. This roadmap is based on the outcome of two workshops, teleconference meetings and review by an independent panel of international experts. Results: This roadmap focuses on the surveillance of HAI within networks of healthcare facilities for the purpose of comparison, prevention and quality improvement initiatives. The roadmap does the following: discusses the selection of surveillance targets, different organizational and methodologic approaches and their advantages, disadvantages and risks; defines key performance requirements of AS systems and suggestions for their design; provides guidance on successful implementation and maintenance; and discusses areas of future research and training requirements for the infection prevention and related disciplines. The roadmap is supported by accompanying documents regarding the governance and information technology aspects of implementing AS. Conclusions: Large-scale implementation of AS requires guidance and coordination within and across surveillance networks. Transitions to large-scale AS entail redevelopment of surveillance methods and their interpretation, intensive dialogue with stakeholders and the investment of considerable resources. This roadmap can be used to guide future steps towards implementation, including designing solutions for AS and practical guidance checklists.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Cost of hospitalised patients due to complicated urinary tract infections: a retrospective observational study in countries with high prevalence of multidrug-resistant Gram-negative bacteria: the COMBACTE-MAGNET, RESCUING study

  • Vallejo Torres, Laura
  • Pujol Rojo, Miquel
  • Shaw Perujo, Evelyn
  • Wiegand, Irith
  • Vigo, Joan Miquel
  • Stoddart, Margaret
  • Grier, Sally
  • Gibbs, Julie
  • Vank, Christiane
  • Cuperus, Nienke
  • van den Heuvel, Leonard
  • Eliakim-Raz, Noa
  • Carratalà, Jordi
  • Vuong, Cuong
  • MacGowan, Alasdair
  • Babich, Tanya
  • Leibovici, Leonard
  • Addy, Ibironke
  • Morris, S. (Stephen), 1971-
  • RESCUING Study Group and Study Sites
Objective: Complicated urinary tract infections (cUTIs) impose a high burden on healthcare systems and are a frequent cause of hospitalisation. The aims of this paper are to estimate the cost per episode of patients hospitalised due to cUTI and to explore the factors associated with cUTI-related healthcare costs in eight countries with high prevalence of multidrug resistance (MDR). Design: This is a multinational observational, retrospective study. The mean cost per episode was computed by multiplying the volume of healthcare use for each patient by the unit cost of each item of care and summing across all components. Costs were measured from the hospital perspective. Patient-level regression analyses were used to identify the factors explaining variation in cUTI-related costs. Setting: The study was conducted in 20 hospitals in eight countries with high prevalence of multidrug resistant Gram-negative bacteria (Bulgaria, Greece, Hungary, Israel, Italy, Romania, Spain and Turkey). Participants: Data were obtained from 644 episodes of patients hospitalised due to cUTI. Results: The mean cost per case was 5700, with considerable variation between countries (largest value 7740 in Turkey; lowest value 4028 in Israel), mainly due to differences in length of hospital stay. Factors associated with higher costs per patient were: type of admission, infection source, infection severity, the Charlson comorbidity index and presence of MDR. Conclusions: The mean cost per hospitalised case of cUTI was substantial and varied significantly between countries. A better knowledge of the reasons for variations in length of stays could facilitate a better standardised quality of care for patients with cUTI and allow a more efficient allocation of healthcare resources. Urgent admissions, infections due to an indwelling urinary catheterisation, resulting in septic shock or severe sepsis, in patients with comorbidities and presenting MDR were related to a higher cost.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Retrospective observational study to assess the clinical management and outcomes of hospitalised patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria (RESCUING)

  • Shaw Perujo, Evelyn
  • Addy, Ibironke
  • Stoddart, Margaret
  • Vank, Christiane
  • Grier, Sally
  • Wiegand, Irith
  • Leibovici, Leonard
  • Eliakim-Raz, Noa
  • Vallejo Torres, Laura
  • Morris, S. (Stephen), 1971-
  • MacGowan, Alasdair
  • Carratalà, Jordi
  • Pujol Rojo, Miquel
Introduction: the emergence of multidrug resistant (MDR) Gram-negative bacteria (GNB), including carbapenemase-producing strains, has become a major therapeutic challenge. These MDR isolates are often involved in complicated urinary tract infection (cUTI), and are associated with poor clinical outcomes. The study has been designed to gain insight into the epidemiology, clinical management, outcome and healthcare cost of patients with cUTI, especially in countries with high prevalence of MDR GNB. Methods and analysis: this multinational and multicentre observational, retrospective study will identify cases from 1 January 2013 to 31 December 2014 in order to collect data on patients with cUTI as a cause of hospital admission, and patients who develop cUTI during their hospital stay. The primary end point will be treatment failure defined as the presence of any of the following criteria: (1) signs or symptoms of cUTI present at diagnosis that have not improved by days 5-7 with appropriate antibiotic therapy, (2) new cUTI-related symptoms that have developed within 30 days of diagnosis, (3) urine culture taken within 30 days of diagnosis, either during or after completion of therapy, that grows ≥10(4) colony-forming unit/mL of the original pathogen and (4) death irrespective of cause within 30 days of the cUTI diagnosis. Sample size: 1000 patients afford a power of 0.83 (α=0.05) to detect an absolute difference of 10% in the treatment failure rate between MDR bacteria and other pathogens. This should allow for the introduction of about 20 independent risk factors (or their interaction) in a logistic regression model looking at risk factors for failure. Ethics and dissemination: approval will be sought from all relevant Research Ethics Committees. Publication of this study will be considered as a joint publication by the participating investigator leads, and will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Gut to lung translocation and antibiotic mediated selection shape the dynamics of Pseudomonas aeruginosa in an ICU patient

  • Wheatley, Rachel M.|||0000-0003-1212-2286
  • Caballero, Julio Diaz
  • van der Schalk, Thomas E.|||0000-0001-7493-4082
  • De Winter, Fien H. R.|||0000-0003-3803-7813
  • Shaw, Liam P.
  • Kapel, Natalia
  • Recanatini, Claudia|||0000-0003-0643-7599
  • Timbermont, Leen|||0000-0002-9543-9205
  • Kluytmans, Jan|||0000-0003-2665-6844
  • Esser, Mark|||0000-0003-1689-3475
  • Lacoma, Alicia|||0000-0002-2049-3872
  • Prat i Aymerich, Cristina|||0000-0001-6974-9165
  • Oliver, Antonio|||0000-0001-9327-1894
  • Kumar-Singh, Samir|||0000-0001-9466-6732
  • Malhotra-Kumar, Surbhi|||0000-0001-8699-8905
  • Craig MacLean, R.|||0000-0002-7941-813X
Bacteria have the potential to translocate between sites in the human body, but the dynamics and consequences of within-host bacterial migration remain poorly understood. Here we investigate the link between gut and lung Pseudomonas aeruginosa populations in an intensively sampled ICU patient using a combination of genomics, isolate phenotyping, host immunity profiling, and clinical data. Crucially, we show that lung colonization in the ICU was driven by the translocation of P. aeruginosa from the gut. Meropenem treatment for a suspected urinary tract infection selected for elevated resistance in both the gut and lung. However, resistance was driven by parallel evolution in the gut and lung coupled with organ specific selective pressures, and translocation had only a minor impact on AMR. These findings suggest that reducing intestinal colonization of Pseudomonas may be an effective way to prevent lung infections in critically ill patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients, a randomised controlled trial

  • Chastre, Jean
  • François, Bruno
  • Bourgeois, Marc
  • Komnos, Apostolos
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Rahav, Galia
  • De Schryver, Nicolas
  • Lepape, Alain
  • Koksal, Iftihar
  • Luyt, Charles-Edouard|||0000-0001-7424-2705
  • Sánchez García, Miguel
  • Torres, Antoni|||0000-0002-8643-2167
  • Eggimann, Philippe
  • Koulenti, Despoina
  • Holland, Thomas L.
  • Ali, Omar
  • Shoemaker, Kathryn
  • Ren, Pin
  • Sauser, Julien
  • Ruzin, Alexey
  • Tabor, David E.
  • Akhgar, Ahmad
  • Wu, Yuling
  • Jiang, Yu
  • DiGiandomenico, Antonio
  • Colbert, Susan
  • Vandamme, Drieke
  • Coenjaerts, Frank
  • Malhotra-Kumar, Surbhi|||0000-0001-8699-8905
  • Timbermont, Leen|||0000-0002-9543-9205
  • Oliver, Antonio|||0000-0001-9327-1894
  • Barraud, Olivier
  • Bellamy, Terramika
  • Bonten, Marc
  • Goossens, Herman
  • Reisner, Colin
  • Esser, Mark T.
  • Jafri, Hasan S.
  • Joannidis, Michael
  • Klimscha, Walter
  • De Waele, Elisabeth
  • Devriendt, Jacques
  • Huberlant, Vincent
  • Depuydt, Pieter
  • Van Boxstael, Sam
  • Peric, Mladen
  • Kopic, Jasminka
  • Hanauer, Michal
  • Hruby, Tomas
  • Sramek, Vladimir
  • Svoboda, Petr
  • Vymazal, Tomas
  • Novacek, Martin
  • Annane, Djillali
  • Mira, Jean-Paul
  • Souweine, Bertrand
  • Dequin, Pierre-François
  • Meziani, Ferhat
  • Stephan, François
  • Nseir, Saad|||0000-0002-7618-0357
  • Gibot, Sebastien
  • Schwebel, Carole
  • Plantefeve, Gaetan
  • Diehl, Jean-Luc
  • Richard, Christian
  • Lamer, Christian
  • Klouche, Kada
  • Jaber, Samir
  • Zakynthinos, Epaminondas
  • Filntisis, Georgios
  • Zakynthinos, Spyros
  • Koutsoukou, Antonia
  • Saroglou, Georgios
  • Nikolaou, Charikleia
  • Vlachogianni, Glykeria
  • Pnevmatikos, Ioannis
  • Mandragos, Konstantinos
  • Kremer, Ildiko
  • Rozgonyi, Zsolt Dezso
  • Marjanek, Zsuzsa
  • Martin-Loeches, Ignacio|||0000-0002-5834-4063
  • Singer, Pierre
  • Van Heerden, Vernon
  • Carmeli, Yehuda
  • Póvoa, Pedro|||0000-0002-7069-7304
  • AlvarezSeoane, Antonio
  • Moura, Pedro
  • Gonzalez, Filipe
  • Ramírez, Paula|||0000-0002-7598-3350
  • Torres Marti, Antonio
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Oteiza, Lorena
  • Escudero, Dolores
  • Piacentini Gómez, Enrique
  • Vera Artazcoz, Paula|||0000-0003-3346-5093
  • Tamayo, Luis
  • Gonzalez Gallego, Miguel Angel
  • Suberviola Canas, Borja
  • Figueira, Iglesias
  • Leon, Rafael
  • Korten, Volkan
  • Akova, Murat|||0000-0002-6904-9473
  • Wyncoll, Duncan
  • Whitehouse, Tony
  • Hopkins, Phil
  • Sim, Malcolm
  • Golan, Yoav
  • Zervos, Marcus
  • Vazquez, Jose
  • Cherabuddi, Kartikeya
  • Smulian, George
  • Rouphael, Nadine
  • Welker, James
  • Sims, Mathew
  • Van Duin, David
  • McCarthy, Todd
  • Polk, Christopher
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia was assessed in PA-colonised mechanically ventilated subjects. Methods: EVADE (NCT02696902) was a phase 2, randomised, parallel-group, double-blind, placebo-controlled study in Europe, Turkey, Israel, and the USA. Subjects ≥ 18 years old, mechanically ventilated, tracheally colonised with PA, and without new-onset pneumonia, were randomised (1:1:1) to MEDI3902 500, 1500 mg (single intravenous dose), or placebo. The primary efficacy endpoint was the incidence of nosocomial PA pneumonia through 21 days post-dose in MEDI3902 1500 mg versus placebo, determined by an independent adjudication committee. Results: Even if the initial sample size was not reached because of low recruitment, 188 subjects were randomised (MEDI3902 500/1500 mg: n = 16/87; placebo: n = 85) between 13 April 2016 and 17 October 2019. Out of these, 184 were dosed (MEDI3902 500/1500 mg: n = 16/85; placebo: n = 83), comprising the modified intent-to-treat set. Enrolment in the 500 mg arm was discontinued due to pharmacokinetic data demonstrating low MEDI3902 serum concentrations. Subsequently, enrolled subjects were randomised (1:1) to MEDI3902 1500 mg or placebo. PA pneumonia was confirmed in 22.4% (n = 19/85) of MEDI3902 1500 mg recipients and in 18.1% (n = 15/83) of placebo recipients (relative risk reduction [RRR]: - 23.7%; 80% confidence interval [CI] - 83.8%, 16.8%; p = 0.49). At 21 days post-1500 mg dose, the mean (standard deviation) serum MEDI3902 concentration was 9.46 (7.91) μg/mL, with 80.6% (n = 58/72) subjects achieving concentrations.